Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?
作者信息
Scheen André J
机构信息
Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Liège University and Academic Hospital of Liège (CHU Liège), B-4000 Liège, Belgium.
出版信息
Diabetes Res Clin Pract. 2019 Jan;147:169-171. doi: 10.1016/j.diabres.2018.10.023. Epub 2018 Nov 2.
Abstract
摘要
Zotero 插件